SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's earnings have sparked intense debate, with a revenue beat overshadowed by an EPS miss, triggering volatility. The community is focused on the upcoming conference call with Elon Musk, anticipating insights on robotaxis and AI. Broader discussions revolve around Tesla's valuation and future growth prospects in the evolving EV market.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst anticipation for upcoming earnings, with the community eager for updates on partnerships and production milestones. Discussions revolve around the potential impact of earnings on the stock's price, as well as speculation regarding a possible partnership with Panasonic and the unveiling of a second OEM. Despite some concerns about market conditions and short selling, many investors express long-term confidence in the company's technology and future prospects in the battery sector.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community rallies around the idea of 'OG memes' making a comeback, emphasizing community building and a rejection of traditional 'coining'. The community is expressing strong conviction, with many calling for moonshot listings and celebrating its current trending status. Talk centers around the idea that while markets may be uncertain, the 'rage' will continue.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors discuss the recent earnings call, pipeline progress, and cash runway, with some expressing concerns about cash burn while others highlight the potential for partnerships and buyout opportunities. The community is weighing the company's prospects in the competitive GLP-1 market against its financial health and the CEO's strategy. Discussions also involve technical analysis, short positions, and potential catalysts for stock movement.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a recent breakthrough in quantum computing with HSBC, demonstrating improved bond trading predictions, which has sparked excitement about the company's leadership in the sector. The community is discussing IBM's growing AI and quantum capabilities and the potential impact on its stock value. Broader market context includes IBM's strategic shift towards AI and cloud computing.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending due to a significant earnings miss, sparking concerns about rising medical costs and the impact of Medicaid trends across the healthcare sector. Community members are discussing potential support levels and comparing MOH to competitors like CNC and UNH, while also speculating on potential catalysts like ACA subsidy extensions. The broader context involves uncertainty around government healthcare policy and its effect on managed care organizations.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is trending amid discussions about earnings, with some celebrating a significant beat while others express concerns about tariffs and broader market conditions. The community is focused on whether the stock's upward momentum can be sustained. Bullish sentiment seems to be building around the company's potential in AI and memory markets.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending as investors react to sector-wide pressures, particularly following Molina's earnings miss, which has sparked concerns about Medicaid margins and dragged down other healthcare stocks. The community is actively debating whether the dip represents a buying opportunity ahead of Centene's upcoming earnings, with some highlighting its undervalued status and potential for a V-shaped recovery contingent upon ACA subsidy extensions and positive earnings.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals is trending due to positive Phase 2a trial results for its AP-SA02 drug, showing promise in treating Staphylococcus aureus bacteremia; the community is excited about the potential for advancement into Phase 3 and the drug's efficacy against antibiotic-resistant strains. Some traders are pointing to the low float and a partnership with Gilead as reasons to be bullish, while others caution about potential dilution and the company's cash runway.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group ($UNH) is trending amidst mixed sentiment following competitor earnings and broader sector concerns. Community discussions revolve around margin pressures, potential impacts from government policies, and speculation on upcoming earnings. Some traders anticipate a pre-earnings rally while others remain cautious, citing regulatory scrutiny and economic uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR...

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to...

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business...

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives...

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update...

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer...

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment...

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

CTOR
Citius Oncology Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CTOR News

CTORCitius Oncology Inc.